Literature DB >> 19501252

Surgical treatment of obesity.

Megan K Baker1, T Karl Byrne, Mark E Feldmann.   

Abstract

Once an obese patient has failed attempts at diet modification, physical activity, pharmacologic treatment, and possibly even complementary and alternative therapies, the next step is to consider surgical management. Treatment plans must be customized for individual patients and should involve evaluation by the primary care provider, a dietician, psychologist, and surgeon. Then depending on the individual's needs, comorbidities, and candidacy, a specific surgical intervention may be necessary. These procedures are restrictive, malabsorptive, and a combination of both. Each procedure has its own short-term and long-term complications and must be monitored for the rest of the individual's life.

Entities:  

Mesh:

Year:  2009        PMID: 19501252     DOI: 10.1016/j.pop.2009.01.001

Source DB:  PubMed          Journal:  Prim Care        ISSN: 0095-4543            Impact factor:   2.907


  5 in total

1.  Narcotic addiction following gastric bypass surgery--a case study.

Authors:  Andrea Wendling; Andrea Wudyka
Journal:  Obes Surg       Date:  2011-05       Impact factor: 4.129

2.  Liver: Does bariatric surgery reduce the severity of NAFLD?

Authors:  Helma P Cotrim; Carla Daltro
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2010-01       Impact factor: 46.802

Review 3.  Clinical approaches to non-alcoholic fatty liver disease.

Authors:  Katherine J P Schwenger; Johane P Allard
Journal:  World J Gastroenterol       Date:  2014-02-21       Impact factor: 5.742

4.  Momordica charantia (bitter melon) inhibits primary human adipocyte differentiation by modulating adipogenic genes.

Authors:  Pratibha V Nerurkar; Yun-Kung Lee; Vivek R Nerurkar
Journal:  BMC Complement Altern Med       Date:  2010-06-29       Impact factor: 3.659

5.  Predictors of weight loss and maintenance in patients treated with antiobesity drugs.

Authors:  Federica Guaraldi; Uberto Pagotto; Renato Pasquali
Journal:  Diabetes Metab Syndr Obes       Date:  2011-06-20       Impact factor: 3.168

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.